Antibodies Market Research Report – Segmentation By Type (Monoclonal Antibodies [mAbs] {Oncology, Autoimmune Diseases, Infectious Diseases}, and Antibody-drug Conjugates [ADCs]); By Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, CNS Disorders, Others (Inflammatory, Microbial Diseases, & Others)); By End User (Hospitals, and Specialty Centers, Research Institute, Diagnostics laboratories); By Technology( Western Blotting, Flow Cytometry, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, Others); and Region; - Size, Share, Growth Analysis | Forecast (2024– 2030)
Published: 2024 - January
Report Code: IM-2580
Format:
Region: Global
Chapter 1. Global Antibodies Market– Scope & Methodology
1.1. Market Segmentation
1.2. Scope, Assumptions & Limitations
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. Global Antibodies Market – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.2.1. Demand Side
2.2.2. Supply Side
2.4. Attractive Investment Propositions
2.5. COVID-19 Impact Analysis
Chapter 3. Global Antibodies Market– Competition Scenario
3.1. Market Share Analysis & Company Benchmarking
3.2. Competitive Strategy & Development Scenario
3.3. Competitive Pricing Analysis
3.4. Supplier-Distributor Analysis
Chapter 4. Global Antibodies Market - Entry Scenario
4.1. Regulatory Scenario
4.2. Case Studies – Key Start-ups
4.3. Customer Analysis
4.5. PESTLE Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. Global Antibodies Market- Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. Global Antibodies Market– By Type
6.1. Introduction/Key Findings
6.2. Monoclonal Antibodies [mAbs]
6.2.1. Oncology,
6.2.2. Autoimmune Diseases,
6.2.3. Infectious Diseases
6.2.4. Antibody-drug Conjugates [ADCs]
6.3. Y-O-Y Growth trend Analysis By Type
6.4. Absolute $ Opportunity Analysis By Type , 2024-2030
Chapter 7. Global Antibodies Market– By Technology
7.1. Introduction/Key Findings
7.2 Western Blotting
7.3. Flow Cytometry
7.4. Immunohistochemistry
7.5. Immunofluorescence
7.6. Immunoprecipitation
7.7. Others
7.8. Y-O-Y Growth trend Analysis By Technology
7.9. Absolute $ Opportunity Analysis By Technology , 2024-2030
Chapter 8. Global Antibodies Market– By End-User
8.1. Introduction/Key Findings
8.2. Hospitals
8.3. Specialty Centers
8.4. Research Institute
8.5. Diagnostics laboratories
8.6. Y-O-Y Growth trend Analysis End-User
8.7. Absolute $ Opportunity Analysis Type, 2024-2030
Chapter 9. Global Antibodies Market– By Indication
9.1. Introduction/Key Findings
9.2. Cancer
9.3. Autoimmune Diseases
9.4. Infectious Diseases
9.5. Cardiovascular Diseases
9.6. CNS Disorders
9.7. Others (Inflammatory, Microbial Diseases, & Others)
9.8. Y-O-Y Growth trend Analysis Indication
9.9. Absolute $ Opportunity Analysis Indication , 2024-2030
Chapter 10. Global Antibodies Market, By Geography – Market Size, Forecast, Trends & Insights
10.1. North America
10.1.1. By Country
10.1.1.1. U.S.A.
10.1.1.2. Canada
10.1.1.3. Mexico
10.1.2. By Type
10.1.3. By Technology
10.1.4. By Indication
10.1.5. End-User
10.1.6. Countries & Segments - Market Attractiveness Analysis
10.2. Europe
10.2.1. By Country
10.2.1.1. U.K.
10.2.1.2. Germany
10.2.1.3. France
10.2.1.4. Italy
10.2.1.5. Spain
10.2.1.6. Rest of Europe
10.2.2. By Type
10.2.3. By Technology
10.2.4. By Indication
10.2.5. End-User
10.2.6. Countries & Segments - Market Attractiveness Analysis
10.3. Asia Pacific
10.3.2. By Country
10.3.2.2. China
10.3.2.2. Japan
10.3.2.3. South Korea
10.3.2.4. India
10.3.2.5. Australia & New Zealand
10.3.2.6. Rest of Asia-Pacific
10.3.2. By Type
10.3.3. By Technology
10.3.4. By Indication
10.3.5. End-User
10.3.6. Countries & Segments - Market Attractiveness Analysis
10.4. South America
10.4.3. By Country
10.4.3.3. Brazil
10.4.3.2. Argentina
10.4.3.3. Colombia
10.4.3.4. Chile
10.4.3.5. Rest of South America
10.4.2. By Type
10.4.3. By Technology
10.4.4. By Indication
10.4.5. End-User
10.4.6. Countries & Segments - Market Attractiveness Analysis
10.5. Middle East & Africa
10.5.4. By Country
10.5.4.4. United Arab Emirates (UAE)
10.5.4.2. Saudi Arabia
10.5.4.3. Qatar
10.5.4.4. Israel
10.5.4.5. South Africa
10.5.4.6. Nigeria
10.5.4.7. Kenya
10.5.4.10. Egypt
10.5.4.10. Rest of MEA
10.5.2. By Type
10.5.3. By Technology
10.5.4. By Indication
10.5.5. End-User
10.5.6. Countries & Segments - Market Attractiveness Analysis
Chapter 11. Global Antibodies Market– Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
11.1 Abcam Plc.
11.2. Merck KGaA
11.3. Thermo Fisher Scientific, Inc.
11.4. Cell Signalling Technology, Inc.
11.5. Santa Cruz Biotechnology Inc.
11.6. PerkinElmer, Inc.
11.7. Becton, Dickinson and Company
11.8. Bio-Techne Corporation
11.9. Proteintech Group, Inc.
11.10. Jackson Immuno Research Inc.
Download Sample
Choose License Type
2500
4250
5250
6900
Frequently Asked Questions
The Global Antibodies Market reached USD 162.17 Billion in 2023 and is projected to witness lucrative growth by reaching up to USD 343.33 Billion by 2030. The market is growing at a CAGR of 11.31% during the forecast period (2024-2030).
The worldwide Global Antibodies Market growth is estimated to be 11.31% from 2024 to 2030.
The Global Antibodies Market is segmented by Type (Monoclonal Antibodies [mAbs] {Oncology, Autoimmune Diseases, Infectious Diseases}, and Antibody-drug Conjugates [ADCs]).
The growing use of monoclonal antibodies, customised treatment, and biotechnology developments are anticipated to be major trends in the global antibody market in the future. Opportunities to support further growth and innovation in the industry include the investigation of novel antibody forms, the development of biosimilars, and the expansion of therapeutic uses.
The global market for antibodies saw a notable increase as a result of the COVID-19 pandemic, mainly due to the pressing need for antibody-based treatments and diagnostics. During this time, monoclonal antibodies were developed and approved more quickly for use in both prevention and treatment, which led to a significant increase in investment and innovation in the field.
